We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.9 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
0.9 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$46.7M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$21M
5
ABMD
Abiomed Inc
ABMD
+$18.7M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$49M
2
HCA icon
HCA Healthcare
HCA
+$27.9M
3
MASI icon
Masimo
MASI
+$27.2M
4
ARKG icon
ARK Genomic Revolution ETF
ARKG
+$21.6M
5
RCM icon
R1 RCM Inc. Common Stock
RCM
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABMD
26
DELISTED
Abiomed Inc
ABMD
$17.2M 1.22%
+69,297
New +$18.7M
2022 Q2
0 quarters
NTRA icon
27
Natera
NTRA
$56.7B
$16.9M 1.2%
+475,655
New +$17.6M
2022 Q2
0 quarters
GH icon
28
Guardant Health
GH
$21.3B
$16.4M 1.17%
406,375
+193,172
+91% +$9.57M
2021 Q1
5 quarters
TNDM icon
29
Tandem Diabetes Care
TNDM
$1.13B
$15.2M 1.08%
+256,268
New +$21M
2022 Q2
0 quarters
CLDX icon
30
Celldex Therapeutics
CLDX
$2.16B
$14.9M 1.06%
552,388
-84,065
-13% -$2.44M
2021 Q4
2 quarters
XENE icon
31
Xenon Pharmaceuticals
XENE
$3.24B
$14.2M 1.01%
465,911
+55,890
+14% +$1.69M
2021 Q4
2 quarters
RCM icon
32
DELISTED
R1 RCM Inc. Common Stock
RCM
$12.4M 0.88%
590,819
-770,687
-57% -$17.5M
2021 Q2
4 quarters
MRVI icon
33
Maravai LifeSciences
MRVI
$1.01B
$12.1M 0.86%
+425,364
New +$13.5M
2022 Q2
0 quarters
LNTH icon
34
Lantheus
LNTH
$6.51B
$11.9M 0.85%
+180,053
New +$11.4M
2022 Q2
0 quarters
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$31B
$11.5M 0.82%
78,987
+26,116
+49% +$3.7M
2021 Q1
5 quarters
MASS icon
36
908 Devices
MASS
$465M
$9.69M 0.69%
470,444
+253,295
+117% +$4.26M
2022 Q1
1 quarter
LQDA icon
37
Liquidia Corp
LQDA
$3.07B
$9.15M 0.65%
2,099,708
+722,218
+52% +$3.73M
2021 Q1
5 quarters
QGEN icon
38
Qiagen
QGEN
$9.53B
$8.96M 0.64%
179,093
-2,633
-1% -$128K
2020 Q2
8 quarters
IWM icon
39
PUT
iShares Russell 2000 ETF
IWM
$76.2B
$8.47M 0.6%
+50,000
New +$9.22M
2022 Q2
0 quarters
TARO icon
40
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$7.97M 0.57%
220,390
+104
+0% +$3.96K
2019 Q4
10 quarters
HQY icon
41
HealthEquity
HQY
$7.61B
$7.8M 0.55%
127,043
-17,097
-12% -$1.1M
2021 Q2
4 quarters
MRUS icon
42
DELISTED
Merus
MRUS
$6.52M 0.46%
287,806
+210,957
+275% +$4.4M
2021 Q4
2 quarters
ILMN icon
43
Illumina
ILMN
$39.6B
$6.5M 0.46%
36,253
-3,591
-9% -$917K
2022 Q1
1 quarter
HUM icon
44
Humana
HUM
$49.6B
$5.24M 0.37%
+11,170
New +$4.97M
2022 Q2
0 quarters
RDUS icon
45
DELISTED
Radius Health, Inc.
RDUS
$5.21M 0.37%
502,587
+200,415
+66% +$1.49M
2022 Q1
1 quarter
CLDX icon
46
CALL
Celldex Therapeutics
CLDX
$2.16B
$5.17M 0.37%
+191,600
New +$5.56M
2022 Q2
0 quarters
VRDN icon
47
Viridian Therapeutics
VRDN
$2.16B
$5.16M 0.37%
445,592
+289,849
+186% +$3.9M
2021 Q3
3 quarters
FOLD icon
48
DELISTED
Amicus Therapeutics
FOLD
$5.14M 0.37%
+478,245
New +$3.94M
2022 Q2
0 quarters
MRK icon
49
CALL
Merck
MRK
$360B
$4.44M 0.32%
48,700
– –
2021 Q2
4 quarters
PBYI icon
50
Puma Biotechnology
PBYI
$507M
$4.09M 0.29%
1,435,077
+10,427
+0.7% +$25.9K
2021 Q3
3 quarters
1
2
3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.